TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02696434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: daily dosing
Study: NCT05213026

Intervention type: PROCEDURE
Intervention: Regenerative endodontics
Description: Regenerative endodontic procedure with 3 Mix-MP
Study: NCT04126096

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skin Testing beta-lactams
Description: Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
Study: NCT03636945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET at 18F-FDOPA
Description: 18F-fluorodihydroxyphenylalanine (18F-FDOPA) PET imaging
Study: NCT02105636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study: NCT01439087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGH Optical Frequency Domain Imaging (OFDI) System
Description: Imaging of Colonic Polyps with OFDI system
Study: NCT03413410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Patients with acute coronary syndrome take metoprolol during hospital and after discharge in the optimal dosing pathway.
Study: NCT03010579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: Erythropoietin will be administered subcutaneously (s.c.) at the dose of 10 000 IU, three times a week. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron supplementation
Description: If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.
Study: NCT05551481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: To evaluate the clinical performance of indirect resin composite restorations, which were luted with two different resin cement, in posterior teeth for up to 2 years.
Description: resin cement (Variolink II, Ivoclar Vivadent)-self-adhesive resin cement (Relyx U200, 3M ESPE)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: To evaluate the clinical performance of indirect resin composite restorations, which were luted with two different resin cement, in posterior teeth for up to 2 years.
Description: resin cement (Variolink II, Ivoclar Vivadent)-self-adhesive resin cement (Relyx U200, 3M ESPE)
Study: NCT02329106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and diaphragmatic dome.
Study: NCT01391143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGA271
Description: Up to 9 dose escalation cohorts will be enrolled to determine the maximum tolerated dose of MGA271. Patients with evidence of clinical benefit will be allowed to continue therapy at the same dose once per week for 3 weeks out of every 4-week cycle until documented progression.~Patients treated in the Expansion Segment at the maximum administered dose will receive weekly, uninterrupted infusions of MGA271 in 8 week cycles for up to 12 cycles.
Study: NCT04284761

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bicalutamide implant
Description: Biolen bicalutamide implant
Study: NCT00358215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT01806935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC086

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00458393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daily TDF/FTC
Description: daily oral medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily oral medication
Study: NCT03184818

Intervention type: OTHER
Intervention: Advanced care
Description: The pharmacist will assess for symptoms of urinary tract infection and, for patients in Arm 1, prescribe antibacterials when appropriate. For patients in Arm 2, pharmacists will ensure optimal therapy and adapt or perform therapeutic substitution when appropriate (or work with the patient to discontinue therapy or just put the prescription on file in instances where the patient is assessed to have asymptomatic bacteriuria for which treatment is inappropriate).
Study: NCT03246802

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR partial prostate brachytherapy
Description: temporary radioactive implant
Study: NCT01507532

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacokinetic monitoring
Description: pharmacokinetic monitoring
Study: NCT03303391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradialytic Blood Pressure Slope Based Ultrafiltration
Description: Algorithmic Determination of ultrafiltration based on intradialytic blood pressure slopes calculated at the beginning of each month from the prior two weeks of dialysis treatments
Study: NCT01134289

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar sympathetic block
Description: unilateral lumbar sympathetic block at L3 level using 0.2% chirocaine under C-arm fluoroscopy
Study: NCT03129295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPC-SHRC
Description: Oral tablet four times a day for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Oral tablet four times a day for 3 days
Study: NCT00858468

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine (2004-2005 Formulation)
Description: 0.25 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine (2004-2005 Formulation)
Description: 0.25 mL, Intramuscular
Study: NCT04655534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Warm-up (IMW)
Description: The IMW protocol applied before each inspiratory muscle training (IMT) session by using a threshold inspiratory muscle trainer. The IMW protocol consists of 2 sets of 30 breaths in 40% of the maximal inspiratory pressure (MIP), with 1 min rest between sets. The intensity of MIP adjusted by two weekly MIP measurements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: The IMT applied twice a day as 30 breath repetitions at 60% of the maximal inspiratory pressure (MIP). The intensity of MIP adjusted by two weekly MIP measurements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: The IMT applied twice a day as 30 breath repetitions at 60% of the maximal inspiratory pressure (MIP). The intensity of MIP adjusted by two weekly MIP measurements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory exercises and aerobic exercise program
Description: Then the respiratory exercises and aerobic exercise program performed in both groups in each session. Aerobic exercise program; After 5 min of general body warming, applied 20 min with a load of 4-6 according to the modified Borg scale on the treadmill, finished with 5 min whole body cool-down. All program applied to 3 days a week for 8 weeks under the supervision of a physiotherapist and other days of the week without a supervisor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory exercises and aerobic exercise program
Description: Then the respiratory exercises and aerobic exercise program performed in both groups in each session. Aerobic exercise program; After 5 min of general body warming, applied 20 min with a load of 4-6 according to the modified Borg scale on the treadmill, finished with 5 min whole body cool-down. All program applied to 3 days a week for 8 weeks under the supervision of a physiotherapist and other days of the week without a supervisor.
Study: NCT01202552

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal influenza vaccine
Description: receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal influenza vaccine
Description: receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site and group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal influenza vaccine
Description: receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
Study: NCT01260584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: One 10 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: One 75 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
Study: NCT02026869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is taken either orally or vaginally every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is taken either orally or vaginally every 12 hours
Study: NCT02600585

Intervention type: BIOLOGICAL
Intervention: Recombinant Influenza Vaccine
Description: Intramuscular injection of study vaccine

Intervention type: BIOLOGICAL
Intervention: Inactivated Influenza Vaccine
Description: Intramuscular injection of study vaccine
Study: NCT04187430

Intervention type: BEHAVIORAL
Intervention: Retrospective
Description: Those patients with a positive sample for ICD will be randomly selected from the microbiology database.
Study: NCT00445744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBPC transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic transplantation
Study: NCT04081116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symmetric settings (high pressures/fast rate)
Description: Describes settings on the MI-E device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symmetric settings (high pressures/fast rate)
Description: Describes settings on the MI-E device

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Symmetric settings (high pressures/fast rate)
Description: Describes settings on the MI-E device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asymmetric settings (Pi<Pe/Ti>Te)
Description: Lower insufflation pressures at longer times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asymmetric settings (Pi<Pe/Ti>Te)
Description: Lower insufflation pressures at longer times

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Asymmetric settings (Pi<Pe/Ti>Te)
Description: Lower insufflation pressures at longer times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preinclusion settings
Description: Settings in use at start of study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preinclusion settings
Description: Settings in use at start of study

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Preinclusion settings
Description: Settings in use at start of study
Study: NCT02236078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose isoniazid
Description: See arm description
Study: NCT01037816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FS-67 Patch
Description: One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
Study: NCT00926536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-arm CT + DSA as needed
Description: C-arm CT images obtained and supplemented with DSA if needed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DSA only
Description: DSA imaging only
Study: NCT04273932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium aspartate of lithium carbonate will be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium aspartate of lithium carbonate will be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium aspartate of lithium carbonate will be administered by mouth.
Study: NCT02009371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright Light therapy
Description: In this group, participants will be exposed to the LED treatment device (lightbox) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: dim Red Light therapy
Description: In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
Study: NCT04565821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPD Probe via TNIT
Description: A total of 10 healthy adult volunteers will be enrolled in this study. All consented participants will be receive the same intervention. A Nasal tube will be inserted through nares until reaching the small intestine. This will be confirmed by m-mode OCT. Once secured, we will start infusing Ionic solution into the intestine so that IPD Probe can measure the potential difference between this and the control reading. The control reading is measured by infusing the same ionic solution subcutaneously on large muscle groups.
Study: NCT04687566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: The participants will take dextromethorphan 60 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: The participants will take memantine 5 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan and memantine
Description: The participants will take dextromethorphan (60 mg per day) and memantine (5 mg per day) combination, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will take the placebo pills, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
Study: NCT02166749

Intervention type: PROCEDURE
Intervention: Subtotal abdominal hysterectomy
Description: Comparison of women undergoing subtotal abdominal hysterectomy (n=107) and women with total abdominal hysterectomy (n=105) a mean of 33 years ago.

Intervention type: PROCEDURE
Intervention: Subtotal abdominal hysterectomy
Description: Comparison of women undergoing subtotal abdominal hysterectomy (n=107) and women with total abdominal hysterectomy (n=105) a mean of 33 years ago.
Study: NCT02070978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 75 mg
Description: Participants who received atacicept 75 milligram (mg) as once-weekly subcutaneous injection in the core study ADDRESS II continued to receive this dose during this LTE study. Participants in this reporting arm received the medication up to a maximum of 143.7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Description: Participants who received placebo in the core study ADDRESS II switched to receive atacicept 150 mg as once-weekly subcutaneous injection for up to a maximum of 97.7 weeks during this LTE study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Description: Participants who received atacicept 150 mg in core study ADDRESS II continued to receive atacicept 150 mg as once-weekly subcutaneous injection during this LTE study up to a maximum of 97.9 weeks.
Study: NCT01643278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02572856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: Apply Dexcom Gen 6 Professional CGM sensor at least 2.5 hours prior to surgery Configure CGM so that its measurements are blinded. Setup CGM to make continuous glucose measurements during and after surgery. Download CGM measurement data after study and compare measurements against glucose measurements made for clinical care.
Study: NCT03762005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRT guided resuscitation
Description: Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to capillary refill time (CRT)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactate guided resuscitation
Description: Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to lactate levels
Study: NCT04187430

Intervention type: BEHAVIORAL
Intervention: Prospective
Description: After the routine identification of a case of DCI by the microbiology laboratory, those new cases will be included in the study.
Study: NCT03311269

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClariVein RES
Description: ClariVein system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClariVein RES
Description: ClariVein system

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Tetradecyl Sulfate 1% Injection
Description: Sodium Tetradecyl Sulfate STS 1% Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Tetradecyl Sulfate 3% Injection
Description: Sodium Tetradecyl Sulfate 3% Injection
Study: NCT00935259

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: 40 mg once daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40 mg once daily for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
Study: NCT01051102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Single dose of 0.5 U/kg body weight injected s.c. (under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
Study: NCT00937521

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal B vaccine
Description: Vaccine candidate formulation I

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal B vaccine
Description: Vaccine candidate formulation II
Study: NCT01505179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
Study: NCT02156973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video information
Description: A six minute information film to address the common themes raised by patients. This will clearly show the scanner, discuss the use of beta-blockers and radiation, and explain the likely side effects of x-ray dye (which can be alarming if patients are not expecting them). In this way we hope patients will be better prepared for the scan.
Study: NCT02773277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: head-impulse testing
Description: all patients will receive quantitative head impulse testing using video goggles for all six semicircular canals.